Lancet:恩曲他滨联用替诺福韦艾拉酚胺用于高危人群HIV感染预防

2020-07-25 MedSci原创 MedSci原创

恩曲他滨联用替诺福韦艾拉酚胺对于HIV高危人群感染预防的效果与恩曲他滨联用替诺福韦二吡呋酯相当,且安全性更具优势

对于HIV患者,替诺福韦艾拉酚胺较替诺福韦二吡呋酯,在抗病毒效果,改善肾脏和骨骼安全性方面更具优势。近日研究人员比较了恩曲他滨联用二吡呋酯或艾拉酚胺,用于HIV暴露预防(PrEP)的疗效和安全性。
 
本次研究为III期非劣效性研究,在欧洲和北美HIV高发病率地区开展,自我报告过去12周内发生男男性行为的HIV感染高危人群参与,在200mg恩曲他滨基础上随机接受替诺福韦二吡呋酯(300mg)或替诺福韦艾拉酚胺(25mg)。研究的主要疗效结果是HIV感染。
 
5387名参与者,其中替诺福韦艾拉酚胺组2694人,替诺福韦二吡呋酯组2693人。所有参与者完成48周随访,50%参与者完成96周随访,结果显示替诺福韦艾拉酚胺与替诺福韦二吡呋酯相比在预防HIV感染方面无显著差异,达到非劣性终点。经过8756人-年的随访,22名参与者被诊断为艾滋病毒感染者,其中艾拉酚胺组7名(0.16例感染/100人-年),二吡呋酯组15人(0.34例/100人-年)。两种治疗方案的耐受性都很好,很少有参与者报告因不良事件导致停药。在所有六个预先指定的骨密度和肾脏生物标志物安全终点中,替诺福韦艾拉酚胺优于吡呋酯。
 
研究认为,恩曲他滨联用替诺福韦艾拉酚胺对于HIV高危人群感染预防的效果与恩曲他滨联用替诺福韦二吡呋酯相当,且安全性更具优势。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2020-12-03 howi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1676973, encodeId=6c1816e69735d, content=<a href='/topic/show?id=fad76036028' target=_blank style='color:#2F92EE;'>#替诺福韦艾拉酚胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60360, encryptionId=fad76036028, topicName=替诺福韦艾拉酚胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1627409946, createdName=许安, createdTime=Fri Jan 29 14:40:05 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975970, encodeId=428419e5970a3, content=<a href='/topic/show?id=b014533e4a1' target=_blank style='color:#2F92EE;'>#感染预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53374, encryptionId=b014533e4a1, topicName=感染预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Wed Feb 17 20:40:05 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675078, encodeId=aac116e5078a6, content=<a href='/topic/show?id=7d321022504e' target=_blank style='color:#2F92EE;'>#高危人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102250, encryptionId=7d321022504e, topicName=高危人群)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e95727161035, createdName=Smile2689, createdTime=Sun Nov 08 13:40:05 CST 2020, time=2020-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830754, encodeId=43fa1830e54ae, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Dec 03 08:40:05 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428647, encodeId=7823142864e9a, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515131, encodeId=111f1515131fa, content=<a href='/topic/show?id=6c4c52855a6' target=_blank style='color:#2F92EE;'>#恩曲他滨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52855, encryptionId=6c4c52855a6, topicName=恩曲他滨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=988610719769, createdName=644982816_68283324, createdTime=Mon Jul 27 00:40:05 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033898, encodeId=ffe4103389837, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Sat Jul 25 12:40:05 CST 2020, time=2020-07-25, status=1, ipAttribution=)]
    2020-07-25 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

相关资讯

Blood:细思极恐,15%的HIV阳性者献血时知道自己已感染HIV!

在美国,15%的HIV阳性献血者在献血前几天接受了抗逆转录病毒治疗(ART),也就是说,他/她们明明知道自己已经感染了HIV,但还是去献血了。我们还能安心的输血吗?

Leronlimab预防HIV的传播:已在猕猴上得到确证

生物技术公司CytoDyn开发的leronlimab(PRO 140)是一种CCR5拮抗剂,具有HIV和COVID-19的治疗潜力。

Lancet Infect Dis:cabotegravir的PrEP方案可将HIV发病率降低66%

长效cabotegravir在预防HIV方面比Truvada高69%。

NEJM:HIV患者抗结核方案选择——系统治疗vs检测指导下治疗

在先前未接受ART治疗的免疫功能受到严重抑制的HIV感染成人中,结核病系统治疗方案在降低24或48周患者死亡率或侵袭性细菌病风险方面并不优于试验指导治疗组,并且不良事件风险增加

Blood:外源性抗原成功显著增强免疫耗竭的HIV CAR T细胞扩增

外源性细胞抗原克服内源性低抗原条件,促进体内病毒特异性CAR-T细胞;在停止抗逆转录病毒治疗后,CAR-T细胞可以控制病毒复制,并且可以通过抗PD-1重新激活。